Clinical Trial Update: Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is studying QLS31905 in combination with chemotherapy, with or without QL2107, for CLDN18.2-positive advanced biliary tract cancer; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• QL2107
• QLS31905

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: CLDN18.2-positive Advanced Biliary Tract Cancer | Phase 2 | Status: NOT_YET_RECRUITING